<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - NORETHISTERONE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>NORETHISTERONE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Endometriosis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;15 mg daily for 4&#8211;6 months or longer, to be started on day 5 of cycle; increased to 20&#8211;25 mg daily if required, dose only increased if spotting occurs and reduced once bleeding has stopped.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dysfunctional uterine bleeding (to arrest bleeding)</span>,
                <span class="indication">Menorrhagia (to arrest bleeding)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg 3 times a day for 10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dysfunctional uterine bleeding (to prevent bleeding)</span>,
                <span class="indication">Menorrhagia (to prevent bleeding)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg twice daily, to be taken from day 19 to day 26 of cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dysmenorrhoea</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg 3 times a day for 3&#8211;4 cycles, to be taken from day 5&#8211;24 of cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premenstrual syndrome (but not recommended)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg 2&#8211;3 times a day for several cycles, to be taken from day 19&#8211;26 of cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Postponement of menstruation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                5 mg 3 times a day, to be started 3 days before expected onset (menstruation occurs 2&#8211;3 days after stopping).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Breast cancer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                40 mg daily, increased if necessary to 60 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                200 mg, to be administered within first 5 days of cycle or immediately after parturition (duration 8 weeks), then 200 mg after 8 weeks if required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                350 micrograms daily, dose to be taken at same time each day, starting on day 1 of cycle then continuously, if administration delayed for 3 hours or more it should be regarded as a &#8216;missed pill'.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Masculinisation of female fetuses and other defects reported with non-contraceptive use.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>When used as a contraceptive; caution in severe liver disease and recurrent cholestatic jaundice, avoid in liver tumour.</p>
            </section>
            <section class="generalInformation">
              <p>Avoid in non-contraceptive indications.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution in non-contraceptive indications.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid in patients with a history of liver tumours</li>
            <li>breast cancer (unless progestogens are being used in the management of this condition)</li>
            <li>genital cancer (unless progestogens are being used in the management of this condition)</li>
            <li>history during pregnancy of idiopathic jaundice</li>
            <li>history during pregnancy of pemphigoid gestationis (non-contraceptive indications)</li>
            <li>history during pregnancy of severe pruritus (non-contraceptive indications)</li>
            <li>when used as a contraceptive, history of breast cancer (can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Acne, alopecia, anaphylactoid reactions, breast tenderness, change in libido, depression, disturbance of appetite, dizziness, fluid retention, headache, hirsutism, insomnia (non-contraceptive indications), jaundice, menstrual disturbances, nausea, premenstrual-like syndrome, pruritus, rash, skin reactions, urticaria, vomiting, weight change,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> injection-site reactions,
              </p>
        
            <section class="advice">
                <h3>Cervical cancer</h3>
              <p>Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives (use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years). The risk of cervical cancer with other progestogen-only contraceptives is not yet known.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
                <h3>Missed oral contraceptive pill</h3>
              <p>The following advice is recommended: &#8216;If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days.&#8217;</p><p>The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Diarrhoea and vomiting with oral contraceptives</h3>
              <p>Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Starting routine for oral contraceptives</h3>
              <p>One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment. </p><p>Changing from a combined oral contraceptive: start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones). </p><p>After childbirth: oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Contraceptives by injection</h3>
              <p>Full counselling backed by <i>patient information leaflet</i> required before administration&#8212;likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Asthma
          </li>
          <li>
            cardiac dysfunction
          </li>
          <li>
            conditions that may worsen with fluid retention
          </li>
          <li>
            diabetes (progestogens can decrease glucose tolerance&#8212;monitor patient closely)
          </li>
          <li>
            epilepsy
          </li>
          <li>
            history of depression
          </li>
          <li>
            hypertension
          </li>
          <li>
            migraine
          </li>
          <li>
            susceptibility to thromboembolism (particular caution with high dose)
          </li>
        </ul>
        <ul>
          <li>
              <strong>When used for contraception:</strong>
            active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
              <strong>When used for contraception:</strong>
            arterial disease
          </li>
          <li>
              <strong>When used for contraception:</strong>
            functional ovarian cysts
          </li>
          <li>
              <strong>When used for contraception:</strong>
            history of jaundice in pregnancy
          </li>
          <li>
              <strong>When used for contraception:</strong>
            malabsorption syndromes
          </li>
          <li>
              <strong>When used for contraception:</strong>
            past ectopic pregnancy
          </li>
          <li>
              <strong>When used for contraception:</strong>
            sex-steroid dependent cancer
          </li>
          <li>
              <strong>When used for contraception:</strong>
            systemic lupus erythematosus with positive (or unknown) anti-phospholipid antibodies
          </li>
          <li>
              <strong>When used for contraception:</strong>
            disturbances of lipid metabolism
          </li>
          <li>
              <strong>When used for contraception:</strong>
            history during pregnancy of deterioration of otosclerosis
          </li>
          <li>
              <strong>When used for contraception:</strong>
            history during pregnancy of pruritus
          </li>
          <li>
              <strong>When used for contraception:</strong>
            possible risk of breast cancer
          </li>
        </ul>
        <ul>
          <li>
            <p>The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes mellitus and migraine; evidence for caution in these conditions is unsatisfactory.</p>
          </li>
          <li>
            <p>There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.</p>
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of NORETHISTERONE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,

            <div id="PHP75432"><a href="../medicinalForm/PHP75432.html" data-target="#PHP75432" data-action="load">Tablet</a></div>
            <div id="PHP106979"><a href="../medicinalForm/PHP106979.html" data-target="#PHP106979" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
